Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Post by dt_coreon May 01, 2023 11:10am
125 Views
Post# 35422823

Very positive outlook

Very positive outlookWhile the quarter came in a bit below th emid range of management's guidance the notable pipeline of future similar SaaS wins alongside the $8M per year already announced is fantastically positive. Also the fact that management said they don't need to raise more capital is also positive, though I'm sure some additional shares will be issued to meet contigent libabilites though it's likely to be a mix of cash and stock. Dilution as a result of poor balance sheet management had been a big driver for poor share price performance in 2022 and YTD 2023. Still, even if one were to assume 100% conversion of the $13M Beedie line into stock + contigent libabilites converted ($4.7M in total) + options/warrants/RSU/other then the total amount of FD shares for THNK is 117.7M. Yes that's a lot, however if you take Q4 exiting Adj.EBITDA and add $3M more for the new contract (it'll be higher longer term). then suddenly the company has $9M in EBITDA and $94M in revenue at the current run-rate (that's not including any other future wins management spoke of). Enterprise Value of the company today is around $72.7M so THNK is still trading at a very steep discount. It would seem that $1.00 to $1.20 is a fair target price for the business today and 12 months from now $1.50 to $1.70 if you assume a reasonable number of the SaaS pipeline converts. Of course based on the comments I heard today I'm expecting Q1 to be on the weaker side while Q3 and Q4 will be on the stronger side simply due to seasonality in the business and the natural ramp of new business wins. Overall all though very positive for those planning to hold the name for a few years or longer.
<< Previous
Bullboard Posts
Next >>